0001171843-20-007747 | 10-Q | XBRL Viewer

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

1.	Basis of Presentation, Risks and Uncertainties, and Summary of Significant Accounting Policies

Basis of Presentation

The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, Harvard Bioscience or the Company) as of September 30, 2020 and for the three and nine months ended September 30, 2020 and 2019, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2019 consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which was filed with the SEC on March 16, 2020.

In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of September 30, 2020, results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019 and cash flows for the nine months ended September 30, 2020 and 2019, as applicable, have been made. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the operating results for the full fiscal year or any future periods.

Risks and Uncertainties

On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic. The COVID-19 pandemic has had a negative impact on the Company’s operations to date and the future impacts of the pandemic and any resulting economic impact are largely unknown and rapidly evolving. Since the COVID-19 outbreak in the United States, Europe and elsewhere, many customers, particularly academic research institutions, have been unable to maintain laboratory work which has negatively impacted, and will continue to, negatively impact our sales. Additionally, to ensure business continuity while maintaining a safe environment for employees aligned with guidance from government and health organizations, the Company transitioned the majority of its workforce to work-from-home while implementing social distancing requirements and other measures in factories to allow manufacturing and other personnel essential to production to continue work within our facilities. Business travel was significantly reduced during this period. While the Company has maintained operations under these conditions, these measures represent disruptions which can impact productivity including sales and marketing activities. Accordingly, these conditions in addition to the overall impact on the global economy have negatively impacted our results of operations and cash flows.

As a result of these market and economic conditions, in accordance with the guidelines set forth in ASC 350 and ASC 360, the Company performed an analysis for potential interim impairment indicators of its intangible and other long-lived assets. As of September 30, 2020, the Company concluded there were no impairments of goodwill, other indefinite-lived intangibles, or long-lived assets that resulted from triggering events due to the COVID-19 pandemic.

Summary of Significant Accounting Policies

The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 16, 2020. There have been no material changes in the Company’s significant accounting policies during the three and nine months ended September 30, 2020.

Note 2 - Recently Issued Accounting Pronouncements

9 Months Ended

Sep. 30, 2020

Description of New Accounting Pronouncements Not yet Adopted [Text Block]

2.	Recently Issued Accounting Pronouncements

Accounting Pronouncements to be Adopted

In September 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. The FASB issued several ASUs after ASU 2016-13 to clarify implementation guidance and to provide transition relief for certain entities. ASU 2016-13 is effective for the Company for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is evaluating the impact that adopting ASU 2016-13 and related amendments will have on its consolidated financial position, results of operations and cash flows.

In August 2018, the FASB issued ASU No. 2018-14, Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans (ASU 2018-14), which amends ASC 715 to add, remove and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The ASU is effective for public entities for fiscal years ending after December 15, 2020, with early adoption permitted. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the disclosure in the Company’s Consolidated Financial Statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which enhances and simplifies various aspects of the income tax accounting guidance related to intra-period tax allocation, interim period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim period tax accounting. ASU 2019-12 also amends other aspects of the guidance to reduce complexity in certain areas. ASU 2019-12 is effective for the Company on January 1, 2021. Early adoption is permitted. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company’s Consolidated Financial Statements.

Note 3 - Accumulated Other Comprehensive Loss

9 Months Ended

Sep. 30, 2020

Comprehensive Income (Loss) Note [Text Block]

3.	Accumulated Other Comprehensive Loss

Changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2020 are as follows:

	Foreign currency			Derivatives
	translation			qualifying as			Defined benefit
(in thousands)	adjustments			hedges			pension plans		Total
Balance at December 31, 2019	$	(13,173	)	$	(603	)	$	1,087	$	(12,689	)
Other comprehensive income (loss) before reclassifications		681			(228	)		-		453
Amounts reclassified from AOCI into income		-			262			-		262
Net other comprehensive income		681			34			-		715
Balance at September 30, 2020	$	(12,492	)	$	(569	)	$	1,087	$	(11,974	)

Note 4 - Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2020

Goodwill and Intangible Assets Disclosure [Text Block]

4.	Goodwill and Intangible Assets

Goodwill

The change in the carrying amount of goodwill for the nine months ended September 30, 2020 is as follows:

(in thousands)
Carrying amount at December 31, 2019	$	57,381
Effect of change in currency translation		266
Carrying amount at September 30, 2020	$	57,647

Intangible Assets

			September 30, 2020							December 31, 2019
	Weighted		(in thousands)
	Average Life*				Accumulated							Accumulated
Amortizable intangible assets:	(in years)		Gross		Amortization			Net		Gross		Amortization			Net
Distribution agreements/customer relationships		9.1	$	18,130	$	(7,400	)	$	10,730	$	17,891	$	(6,340	)	$	11,551
Existing technology		5.4		41,347		(22,524	)		18,823		41,222		(19,698	)		21,524
Trade names		5.7		8,668		(4,150	)		4,518		7,692		(3,497	)		4,195
Patents		-		213		(213	)		-		218		(218	)		-
Total amortizable intangible assets			$	68,358	$	(34,287	)	$	34,071	$	67,023	$	(29,753	)	$	37,270
Indefinite-lived intangible assets:									244							1,135
Total intangible assets								$	34,315						$	38,405

* Weighted average life as of September 30, 2020.

Effective January 1, 2020, the Company determined that $0.9 million of tradenames previously classified as indefinite-lived should be classified as amortizing due to anticipated changes in worldwide marketing programs and estimated an economic life of 4 years for this intangible asset.

Intangible asset amortization expense was $1.4 million for each of the three months ended September 30, 2020 and 2019, respectively and was $4.3 million for each of the nine months ended September 30, 2020 and 2019, respectively.

Estimated amortization expense of existing amortizable intangible assets for each of the five succeeding years and thereafter as of September 30, 2020 is as follows:

Year Ending December 31,	Amortization Expense
	(in thousands)
2020 (remainder of year)	$	1,676
2021		5,703
2022		5,672
2023		5,569
2024		5,267
Thereafter		10,184
Total	$	34,071

Note 5 - Balance Sheet Information

9 Months Ended

Sep. 30, 2020

Supplemental Balance Sheet Disclosures [Text Block]

5.	Balance Sheet Information

The following tables provide details of selected balance sheet items as of the periods indicated:

Inventories:

	September 30, 2020		December 31, 2019
	(in thousands)
Finished goods	$	5,311	$	5,561
Work in process		3,897		3,153
Raw materials		13,481		13,347
Total	$	22,689	$	22,061

Other Current Liabilities:

	September 30, 2020		December 31, 2019
	(in thousands)
Compensation and payroll	$	2,218	$	2,554
Professional fees		594		395
Warranty costs		184		252
Customer related costs		1,038		963
Interest		376		425
Other		1,543		1,502
Total	$	5,953	$	6,091

Note 6 - Restructuring and Other Exit Costs

9 Months Ended

Sep. 30, 2020

Restructuring and Related Activities Disclosure [Text Block]

6.	Restructuring and Other Exit Costs

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify operational efficiencies, enhance commercial capabilities and align its cost base and infrastructure with customer needs and its strategic plans. In order to realize these opportunities, the Company undertakes restructuring-type activities from time to time to transform its business.

The following tables summarize restructuring and other exit charges for the periods set forth below:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2020		2019		2020		2019
Cost of revenues	$	-	$	235	$	-	$	235
Severance costs		234		209		1,585		209
Impairment charges		-		460		-		460
Other		85		10		310		10
Restructuring and other exit costs	$	319	$	914	$	1,895	$	914

The following table summarizes the changes in the restructuring liabilities for the nine months ended September 30, 2020:

(in thousands)	Severance			Other			Total
Balance at December 31, 2019	$	364		$	4		$	368
Restructuring and other exit costs		1,585			310			1,895
Non-cash charges		-			(168	)		(168	)
Cash payments		(1,370	)		(117	)		(1,487	)
Balance at September 30, 2020	$	579		$	29		$	608

During the nine months ended September 30, 2019, the Company incurred impairment charges of $1.4 million consisting of pre-restructuring plan charges of $0.9 million to write-off certain in-process research and development intangible assets, and restructuring plan charges of $0.5 million to write-off certain intangible assets as a result of a decision to discontinue a product line and cease operations in its facility in North Carolina.

As of September 30, 2020, the Company had a restructuring liability of $0.6 million which is payable within the next twelve months and has been included in other current liabilities in the consolidated balance sheet.

Note 7 - Related Party Transactions

9 Months Ended

Sep. 30, 2020

7.	Related Party Transactions

In connection with the 2014 acquisitions of Multi Channel Systems MCS GmbH (“MCS”) and Triangle BioSystems, Inc. (“TBSI”), the Company entered into facility lease agreements with the former principal owners of these companies and both became employees of the Company. The TBSI agreement expired on September 30, 2019, and the MCS agreement expires on December 31, 2024. Pursuant to these lease agreements, the Company made rent payments of approximately $0.1 million and $0.2 million for the three and nine months ended September 30, 2020, respectively, and $0.1 million and $0.3 million for the three and nine months ended September 30, 2019, respectively.

Note 8 - Leases

9 Months Ended

Sep. 30, 2020

Lessee, Operating Leases [Text Block]

8.	Leases

The Company has noncancelable operating leases for offices, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through 2024 and thereafter.

The components of lease expense for the three and nine months ended September 30, 2020 and 2019 are as follows:

	Three Months Ended						Nine Months Ended
	September 30, 2020			September 30, 2019			September 30, 2020			September 30, 2019

Operating lease cost	$	565		$	523		$	1,647		$	1,561
Short term lease cost		46			29			131			156
Sublease income		(26	)		(104	)		(158	)		(309	)
Total lease cost	$	585		$	448		$	1,620		$	1,408

Supplemental cash flow information related to the Company's operating leases was as follows:

	Nine Months Ended
	September 30, 2020		September 30, 2019
	(in thousands)
Cash paid for operating lease liabilities:	$	2,041	$	1,815
Right of use assets obtained in exchange for lease obligations:	$	401	$	-

Supplemental balance sheet information related to the Company's operating leases was as follows:

	September 30, 2020			December 31, 2019
	(in thousands)
Operating lease right-of use assets	$	7,927		$	8,463

Current portion, operating lease liabilities	$	2,190		$	2,424
Operating lease liabilities, long term		7,692			8,224
Total operating lease liabilities	$	9,882		$	10,648

Weighted average remaining lease term (in years)	7.6			8.1
Weighted average discount rate		9.2	%		9.2	%

Future minimum lease payments for operating leases, with initial or remaining terms in excess of one year at September 30, 2020, are as follows:

	Operating
	Leases

2021	$	2,198
2022		1,999
2023		1,944
2024		1,897
2025		1,044
Thereafter		5,086
Total lease payments		14,168
Less interest		(4,286	)
Total operating lease liabilities	$	9,882

Note 9 - Capital Stock and Stock-based Compensation

9 Months Ended

Sep. 30, 2020

Shareholders' Equity and Share-based Payments [Text Block]

9.	Capital Stock and Stock-Based Compensation

Fourth Amended and Restated 2000 Stock Option and Incentive Plan

On June 11, 2020, the stockholders of the Company approved the Fourth Amended and Restated 2000 Stock Option and Incentive Plan (the “Fourth A&R Plan”), which plan authorizes the grant of stock options and stock-based awards to officers, employees, non-employee directors and other key persons of the Company and its subsidiaries. The Fourth A&R Plan modified the Company’s Third Amended and Restated 2000 Stock Option and Incentive Plan to, among other things, increase the aggregate number of shares authorized for issuance by 3,700,000 shares and reduce the fungible share ratio for deferred stock awards from 1.79 to 1.49. As of September 30, 2020, there were 3,288,084 shares available for issuance under the Fourth A&R Plan. Under the terms of the Fourth A&R Plan, each restricted stock unit or other deferred stock award that is granted decreases the shares available for grant by 1.49 shares and each restricted stock unit that is cancelled or forfeited increases the shares available for grant by 1.49 shares.

Stock-Based Payment Awards

Stock option and restricted stock unit activity for the nine months ended September 30, 2020 were as follows:

	Stock Options					Restricted Stock Units					Market Condition RSUs
	Stock			Weighted		Restricted					Market
	Options			Average		Stock Units			Grant Date		Condition RSUs			Grant Date
	Outstanding			Exercise Price		Outstanding			Fair Value		Outstanding			Fair Value

Balance at December 31, 2019		2,266,122		$	3.93		1,590,450		$	2.27		529,491		$	1.67
Granted		894,154			2.61		1,001,113			2.73		332,622			2.98
Exercised		(9,994	)		2.56		-			-		-			-
Vested (RSUs)		-			-		(748,096	)		2.34		(233,056	)		1.47
Cancelled/Forfeited		(253,419	)		3.43		(89,864	)		3.27		(39,286	)		3.03
Market Condition RSU - Performance Factor Adjustment		-			-		-			-		233,055			1.47
Balance at September 30, 2020		2,896,863		$	3.56		1,753,603		$	2.46		822,826		$	2.13

As of September 30, 2020, the total compensation costs related to unvested awards not yet recognized is $5.4 million and the weighted average period over which it is expected to be recognized is approximately 2.4 years.

Stock-based compensation expense for the three and nine months ended September 30, 2020 and 2019 was allocated as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(in thousands)
Cost of revenues	$	19	$	13	$	43	$	34
Sales and marketing expenses		92		39		205		68
General and administrative expenses		908		895		2,249		1,975
Research and development expenses		60		40		144		116
Total stock-based compensation expenses	$	1,079	$	987	$	2,641	$	2,193

The Company did not capitalize any stock-based compensation.

The weighted average estimated fair value per share of stock options granted during the nine months ended September 30, 2020 and 2019 was $1.21 The following assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2020:

Volatility	58.3	%
Risk-free interest rate	0.3	%
Expected holding period (in years)	4.4
Dividend Yield	-	%

The weighted average estimated fair value of the Market Condition RSUs that were granted during the nine months ended September 30, 2020 was $2.98. The following assumptions were used to estimate the fair value of the Market Condition RSUs granted during the nine months ended September 30, 2020, using a Monte-Carlo valuation simulation:

Volatility	80.6	%
Risk-free interest rate	0.2	%
Correlation coefficient	0.3
Dividend Yield	-	%

Earnings (Loss) Per Share

Basic earnings (loss) per share is calculated by dividing net income (loss) by the number of weighted average shares of common stock outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options, restricted stock units and Market Condition RSUs into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following:

	Three Months Ended				Nine Months Ended
	September 30 ,2020		September 30, 2019		September 30 ,2020		September 30, 2019
Basic		38,920,041		38,036,261		38,539,703		37,764,489
Dilutive effect of equity awards		-		-		-		-
Diluted		38,920,041		38,036,261		38,539,703		37,764,489

The shares used in calculating the diluted earnings per share of common stock in the above table exclude options, restricted stock units and Market Condition RSUs of approximately 5,473,292 and 4,055,076 as of September 30, 2020 and 2019, respectively, as the impact of these shares would be anti-dilutive.

Note 10 - Long Term Debt

9 Months Ended

Sep. 30, 2020

Long-term Debt [Text Block]

10.

Long Term Debt

As of September 30, 2020, and December 31, 2019, the Company’s borrowings were comprised of:

	September 30, 2020			December 31, 2019
	(in thousands)
Long-term debt:
Term loan	$	43,911		$	54,997
Revolver		450			-
Less: unamortized deferred financing costs		(885	)		(1,180	)
Total debt		43,476			53,817
Less: current installments		(3,200	)		(3,200	)
Less: excess cash flow sweep		-			(4,093	)
Current unamortized deferred financing costs		393			393
Long-term debt	$	40,669		$	46,917

On January 31, 2018, the Company entered into a financing agreement by and among the Company and certain subsidiaries of the Company as borrowers (collectively, the “Borrower”), certain subsidiaries of the Company as guarantors, various lenders from time to time (the “Lenders”), and Cerberus Business Finance, LLC, as collateral agent and administrative agent for the Lenders (the “Financing Agreement”).

The Financing Agreement provides for senior secured credit facilities comprised of a $64.0 million term loan and up to a $25.0 million revolving line of credit subject to available borrowing base. The revolving facility is available for use by the Company and its subsidiaries for general corporate and working capital needs, and other purposes to the extent permitted by the Financing Agreement. Borrowings available under the revolving line of credit are limited to a borrowing base derived from the Company’s eligible accounts receivable and inventory, as defined in the Financing Agreement. As of September 30, 2020, borrowings available under the revolving facility were $7.3 million.

The Financing Agreement contains certain restrictive covenants, including a requirement to maintain a maximum leverage ratio among other financial and non-financial covenants, as defined in the Financing Agreement. The Company was compliant with all covenants under the Financing Agreement as of September 30, 2020. The maximum permitted leverage is the ratio of total debt to consolidated EBITDA, as defined in the Financing Agreement with a maximum ratio of 3.25 as of June 30, 2020 and for all quarters thereafter until the maturity of the Financing Agreement in 2023. Due to the negative impact of the COVID-19 pandemic on the Company’s revenue and consolidated EBITDA, the gap between the leverage ratio and maximum permitted leverage has reduced. During the nine months ended September 30, 2020, the Company made an additional principal payment of $4.7 million on its term loan.

Based on the Company’s current operating plans, including actions taken to mitigate the negative impact of the COVID-19 pandemic on the Company’s business and financial condition, it expects that available cash, cash generated from current operations and debt capacity will be sufficient to finance current operations, any costs associated with restructuring activities and capital expenditures. This assessment includes consideration of the Company’s best estimates of the impact of the COVID-19 pandemic on its financial results. If the negative impact of the COVID-19 pandemic is more significant than anticipated, it may impact the Company’s ability to comply with financial covenants in the future, which would require the Company to seek an amendment or waivers from its lenders, limit access to or require accelerated repayment of the existing credit facilities, or require the Company to pursue alternative financing. There are no assurances that any such alternative financing, if required, could be obtained at terms acceptable to the Company, or at all.

As of September 30, 2020, the weighted average interest rate, net of the impact of the Company’s interest rate swap, on its borrowings was 8.9%. The carrying value of the debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments.

On April 18, 2020, the Company entered into a promissory note with PNC Bank, National Association, which provided for a loan in the amount of $6.1 million (the “PPP Loan”) pursuant to the Paycheck Protection Program (the “PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). On April 23, 2020, the SBA, in consultation with the U.S. Department of the Treasury issued guidance regarding consideration of alternate available sources of liquidity and its impact on qualification for PPP loans. The Company reassessed its business plans and liquidity available under its existing credit facility and elected to repay all PPP funds. The PPP Loan was repaid in full on May 4, 2020.

Note 11 - Derivatives

9 Months Ended

Sep. 30, 2020

Derivative Instruments and Hedging Activities Disclosure [Text Block]

11.

Derivatives

The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not enter into derivative instruments for any purpose other than cash flow hedging. The Company does not speculate using derivative instruments.

By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not exposed to the counterparty’s credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with carefully selected major financial institutions based upon their credit profile.

Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken.

The Company assesses interest rate risk by continually identifying and monitoring changes in interest rate exposures that may adversely impact expected future cash flows and by evaluating hedging opportunities. The Company maintains risk management control systems to monitor interest rate risk attributable to both the Company’s outstanding and forecasted debt obligations as well as the Company’s offsetting hedge positions. The risk management control systems involve the use of analytical techniques, including cash flow sensitivity analysis, to estimate the expected impact of changes in interest rates on the Company’s future cash flows.

The Company uses variable-rate LIBOR debt to finance its operations. The debt obligations expose the Company to variability in interest payments due to changes in interest rates. Management believes that it is prudent to limit the variability of a portion of its interest payments. To meet this objective, management enters into LIBOR based interest rate swap agreements to manage fluctuations in cash flows resulting from changes in the benchmark interest rate of LIBOR. These swaps change the variable-rate cash flow exposure on the debt obligations to fixed cash flows. Under the terms of the interest rate swaps, the Company receives LIBOR based variable interest rate payments and makes fixed interest rate payments, thereby creating the equivalent of fixed-rate debt for the notional amount of its debt hedged.

As disclosed in Note 10, on January 31, 2018, the Company entered into the Financing Agreement with the Lenders, comprised of a $64.0 million term loan and up to a $25.0 million revolving line of credit. Shortly after entering into the Financing Agreement, the Company entered into an interest rate swap contract with PNC Bank with a notional amount of $36.0 million and a termination date of January 1, 2023 in order to hedge the risk of changes in the effective benchmark interest rate (LIBOR) associated with the Company’s term loan. The swap contract converted specific variable-rate debt into fixed-rate debt and fixed the LIBOR rate associated with a portion of the term loan under the Financing Agreement at 2.72%. The interest rate swap was designated as a cash flow hedge instrument in accordance with ASC 815 “Derivatives and Hedging”.

The following table presents the notional amount and fair value of the Company’s derivative instruments as of September 30, 2020 and December 31, 2019:

		September 30, 2020
		Notional Amount		Fair Value (a)
Derivatives instruments	*Balance sheet classification*	(in thousands)
Interest rate swaps	Other long term liabilities	$	24,077	$	(569	)

		December 31, 2019
		Notional Amount		Fair Value (a)
Derivatives instruments	*Balance sheet classification*	(in thousands)
Interest rate swaps	Other long term liabilities	$	28,821	$	(603	)

(a) See Note 12 for the fair value measurements related to these financial instruments.

All of the Company’s derivative instruments are designated as hedging instruments. The Company has structured its interest rate swap agreements to be fully effective in accordance with ASC 815 and as a result, there was no impact to earnings resulting from hedge ineffectiveness. Changes in the fair value of interest rate swaps designated as hedging instruments that effectively offset the variability of cash flows associated with variable-rate, long-term debt obligations are reported in accumulated other comprehensive income (AOCI). These amounts subsequently are reclassified into interest expense as a yield adjustment of the hedged interest payments in the same period in which the related interest affects earnings.

The following table summarizes the effect of derivatives designated as cash flow hedging instruments and their classification within comprehensive loss for the three and nine months ended September 30, 2020 and 2019:

Derivatives in Hedging Relationships	Amount of gain (loss) recognized in OCI on derivative (effective portion)
	Three Months Ended						Nine Months Ended
	September 30, 2020			September 30, 2019			September 30, 2020			September 30, 2019
	(in thousands)
Interest rate swaps	$	(1	)	$	(78	)	$	(228	)	$	(572	)

The following table summarizes the reclassifications out of accumulated other comprehensive loss for the three and nine months ended September 30, 2020 and 2019:

Details about
AOCI Components

Amount reclassified from AOCI into income (effective portion)

Three Months Ended

Nine Months Ended

Location of amount reclassified from AOCI

September 30, 2020

September 30, 2019

September 30, 2020

September 30, 2019

into income (effective portion)

(in thousands)

Interest rate swaps

262

Interest expense

As of September 30, 2020, $0.3 million of deferred losses on derivative instruments accumulated in AOCI are expected to be reclassified to earnings during the next twelve months. Transactions and events expected to occur over the next twelve months that will necessitate reclassifying these derivatives’ losses to earnings include the repricing of variable-rate debt.

Note 12 - Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Text Block]

12.

Fair Value of Financial Instruments

The carrying values of the Company’s cash and cash equivalents, trade accounts receivable and trade accounts payable and short-term debt approximate their fair values because of the short maturities of those instruments. The fair value of the Company’s long-term debt approximates its carrying value and is based on the amount of future cash flows associated with the debt discounted using current borrowing rates for similar debt instruments of comparable maturity.

Fair value measurement is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3—Unobservable inputs based on the Company’s own assumptions.

The following tables present the fair value hierarchy for those assets or liabilities measured at fair value on a recurring basis:

	Fair Value as of September 30, 2020
(in thousands)	Level 1		Level 2			Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	(569	)	$	-	$	(569	)

	Fair Value as of December 31, 2019
	Level 1		Level 2			Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	(603	)	$	-	$	(603	)

The Company uses the market approach technique to value its financial liabilities. The Company’s financial assets and liabilities carried at fair value include derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s interest rate swap agreements was based on LIBOR yield curves at the reporting date.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Note 13 - Revenues

9 Months Ended

Sep. 30, 2020

Revenue from Contract with Customer [Text Block]

13.

Revenues

The following table represents a disaggregation of revenue from contracts with customers. Revenue originating from the following geographic areas for the three and nine months ended September 30, 2020 and 2019 consist of:

	Three Months Ended September 30, 2020
(in thousands)	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	16,128	$	1,933	$	2,215	$	1,575	$	21,851
Service, maintenance and warranty contracts		1,914		229		36		7		2,186
Total revenues	$	18,042	$	2,162	$	2,251	$	1,582	$	24,037

	Three Months Ended September 30, 2019
(in thousands)	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	19,388	$	2,285	$	2,772	$	1,878	$	26,323
Service, maintenance and warranty contracts		822		198		51		24		1,095
Total revenues	$	20,210	$	2,483	$	2,823	$	1,902	$	27,418

	Nine Months Ended September 30, 2020
(in thousands)	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	48,574	$	6,432	$	7,170	$	4,681	$	66,857
Service, maintenance and warranty contracts		3,459		644		109		47		4,259
Total revenues	$	52,033	$	7,076	$	7,279	$	4,728	$	71,116

	Nine Months Ended September 30, 2019
(in thousands)	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	58,979	$	7,814	$	8,956	$	5,675	$	81,424
Service, maintenance and warranty contracts		2,874		624		227		55		3,780
Total revenues	$	61,853	$	8,438	$	9,183	$	5,730	$	85,204

Deferred revenue

The Company had deferred revenue from service contracts and advance payments from customers of approximately $3.6 million and $3.6 million as of September 30, 2020 and 2019, respectively. Changes in deferred revenue from service contracts and advance payments from customers were as follows:

	Three Months Ended September 30, 2020
(in thousands)	Service Contracts			Customer Advances			Total
Balance at June 30, 2020	$	1,413		$	2,239		$	3,652
Deferral of revenue		1,126			198			1,324
Recognition of deferred revenue		(1,041	)		(387	)		(1,428	)
Effect of foreign currency translation		11			-			11
Balance at September 30, 2020	$	1,509		$	2,050		$	3,559

	Three Months Ended September 30, 2019
(in thousands)	Service Contracts			Customer Advances			Total
Balance at June 30, 2019	$	1,593		$	1,939		$	3,532
Deferral of revenue		471			310			781
Recognition of deferred revenue		(358	)		(421	)		(779	)
Effect of foreign currency translation		16			-			16
Balance at September 30, 2019	$	1,722		$	1,828		$	3,550

	Nine Months Ended September 30, 2020
(in thousands)	Service Contracts			Customer Advances			Total
Balance at December 31, 2019	$	1,587		$	2,362		$	3,949
Deferral of revenue		1,956			542			2,498
Recognition of deferred revenue		(2,029	)		(854	)		(2,883	)
Effect of foreign currency translation		(5	)		-			(5	)
Balance at September 30, 2020	$	1,509		$	2,050		$	3,559

	Nine Months Ended September 30, 2019
(in thousands)	Service Contracts			Customer Advances			Total
Balance at December 31, 2018	$	1,659		$	2,161		$	3,820
Deferral of revenue		1,597			561			2,158
Recognition of deferred revenue		(1,550	)		(894	)		(2,444	)
Effect of foreign currency translation		16			-			16
Balance at September 30, 2019	$	1,722		$	1,828		$	3,550

Allowance for Doubtful Accounts

Allowance for doubtful accounts is based on the Company’s assessment of the collectability of accounts receivable. A rollforward of the allowance for doubtful accounts for the nine months ended September 30, 2020 and 2019 is as follows:

	Nine Months Ended September 30,
	2020			2019

Balance, beginning of period	$	325		$	332
Bad debt expense		24			394
Charge-offs and other recoveries		(60	)		(354	)
Effect of foreign currency translation		4			(8	)
Balance, end of period	$	293		$	364

Concentrations

No customer accounted for more than 10% of the revenues for the three and nine months ended September 30, 2020, and 2019. At September 30, 2020, and December 31, 2019, no customer accounted for more than 10% of net accounts receivable.

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Note 14 - Income Tax

9 Months Ended

Sep. 30, 2020

Income Tax Disclosure [Text Block]

14.

Income Tax

Income tax benefit was approximately $(0.3) million for the three months ended September 30, 2020 and income tax benefit was $(0.1) million for the three months September 30, 2019. The effective tax rate was 22.4% for the three months ended September 30, 2020 compared with 2.0% for the same period in 2019.

Income tax expense was approximately $0.5 million for the nine months ended September 30, 2020 and income tax benefit was $(0.4) million for the nine months ended September 30, 2019. The effective tax rate was (6.7)% for the nine months ended September 30, 2020 compared with 6.5% for the same period in 2019.

The difference between the Company’s effective tax rates in 2020 and 2019 compared to the U.S. statutory tax rate of 21% is primarily due to the mix of 2020 forecasted income or losses in the U.S. and foreign tax jurisdictions, the impact of different tax rates in certain foreign jurisdictions, changes to uncertain tax positions, and the impact of the inclusion of foreign income in U.S. taxable income under the GILTI (Global Intangible Low-Taxed Income) tax rules. The effective tax rate in 2020 was also impacted by increases to valuation allowances and changes made by the CARES Act to the limitation on interest expense deductions, including a retroactive change to the calendar year 2019 deduction.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Note 15 - Commitments and Contingent Liabilities

9 Months Ended

Sep. 30, 2020

Commitments and Contingencies Disclosure [Text Block]

15.

Commitments and Contingent Liabilities

On April 14, 2017, representatives for the estate of an individual plaintiff filed a wrongful death complaint with the Suffolk Superior Court, in the County of Suffolk, Massachusetts, against the Company and other defendants, including Biostage, Inc. (f/k/a Harvard Apparatus Regenerative Technology, Inc.), the Company’s former subsidiary that was spun off in 2013, as well as another third party. The complaint seeks payment for an unspecified amount of damages and alleges that the plaintiff sustained terminal injuries allegedly caused by products, including synthetic trachea scaffolds and bioreactors, provided by certain of the named defendants and utilized in connection with surgeries performed by third parties in 2012 and 2013. The Company intends to vigorously defend this case and has contacted the liability insurance carrier for Biostage, Inc. to request defense and indemnification of any losses incurred in connection with this lawsuit. The Company has been informed by such insurance provider that the case has been accepted as an insurable claim under Biostage, Inc.’s product liability insurance policy and that the Company is a named insured under the policy. While the Company believes that such claim is without merit, the Company is unable to predict the ultimate outcome of this litigation.

The Company is involved in various other claims and legal proceedings arising in the ordinary course of business. Based on the consultation with the Company’s legal counsel, the ultimate disposition of such proceedings is not likely to have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows. The Company has not accrued for loss contingencies relating to any such matters because the Company believes that, although unfavorable outcomes in the proceedings are possible, they are not considered by management to be probable and reasonably estimable. If one or more of these matters are resolved in a manner adverse to the Company, the impact on its business, financial condition, results of operations and cash flows could be material.

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, Harvard Bioscience or the Company) as of September 30, 2020 and for the three and nine months ended September 30, 2020 and 2019, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2019 consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which was filed with the SEC on March 16, 2020. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of September 30, 2020, results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019 and cash flows for the nine months ended September 30, 2020 and 2019, as applicable, have been made. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the operating results for the full fiscal year or any future periods.
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic. The COVID-19 pandemic has had a negative impact on the Company’s operations to date and the future impacts of the pandemic and any resulting economic impact are largely unknown and rapidly evolving. Since the COVID-19 outbreak in the United States, Europe and elsewhere, many customers, particularly academic research institutions, have been unable to maintain laboratory work which has negatively impacted, and will continue to, negatively impact our sales. Additionally, to ensure business continuity while maintaining a safe environment for employees aligned with guidance from government and health organizations, the Company transitioned the majority of its workforce to work-from-home while implementing social distancing requirements and other measures in factories to allow manufacturing and other personnel essential to production to continue work within our facilities. Business travel was significantly reduced during this period. While the Company has maintained operations under these conditions, these measures represent disruptions which can impact productivity including sales and marketing activities. Accordingly, these conditions in addition to the overall impact on the global economy have negatively impacted our results of operations and cash flows. As a result of these market and economic conditions, in accordance with the guidelines set forth in ASC 350 and ASC 360, the Company performed an analysis for potential interim impairment indicators of its intangible and other long-lived assets. As of September 30, 2020, the Company concluded there were no impairments of goodwill, other indefinite-lived intangibles, or long-lived assets that resulted from triggering events due to the COVID-19 pandemic.

Note 3 - Accumulated Other Comprehensive Loss (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	Foreign currency			Derivatives
	translation			qualifying as			Defined benefit
(in thousands)	adjustments			hedges			pension plans		Total
Balance at December 31, 2019	$	(13,173	)	$	(603	)	$	1,087	$	(12,689	)
Other comprehensive income (loss) before reclassifications		681			(228	)		-		453
Amounts reclassified from AOCI into income		-			262			-		262
Net other comprehensive income		681			34			-		715
Balance at September 30, 2020	$	(12,492	)	$	(569	)	$	1,087	$	(11,974	)

Note 4 - Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of Goodwill [Table Text Block]

(in thousands)
Carrying amount at December 31, 2019	$	57,381
Effect of change in currency translation		266
Carrying amount at September 30, 2020	$	57,647

Schedule of Intangible Assets and Goodwill [Table Text Block]

			September 30, 2020							December 31, 2019
	Weighted		(in thousands)
	Average Life*				Accumulated							Accumulated
Amortizable intangible assets:	(in years)		Gross		Amortization			Net		Gross		Amortization			Net
Distribution agreements/customer relationships		9.1	$	18,130	$	(7,400	)	$	10,730	$	17,891	$	(6,340	)	$	11,551
Existing technology		5.4		41,347		(22,524	)		18,823		41,222		(19,698	)		21,524
Trade names		5.7		8,668		(4,150	)		4,518		7,692		(3,497	)		4,195
Patents		-		213		(213	)		-		218		(218	)		-
Total amortizable intangible assets			$	68,358	$	(34,287	)	$	34,071	$	67,023	$	(29,753	)	$	37,270
Indefinite-lived intangible assets:									244							1,135
Total intangible assets								$	34,315						$	38,405

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Year Ending December 31,	Amortization Expense
	(in thousands)
2020 (remainder of year)	$	1,676
2021		5,703
2022		5,672
2023		5,569
2024		5,267
Thereafter		10,184
Total	$	34,071

Note 5 - Balance Sheet Information (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of Inventory, Current [Table Text Block]

	September 30, 2020		December 31, 2019
	(in thousands)
Finished goods	$	5,311	$	5,561
Work in process		3,897		3,153
Raw materials		13,481		13,347
Total	$	22,689	$	22,061

Other Current Liabilities [Table Text Block]

	September 30, 2020		December 31, 2019
	(in thousands)
Compensation and payroll	$	2,218	$	2,554
Professional fees		594		395
Warranty costs		184		252
Customer related costs		1,038		963
Interest		376		425
Other		1,543		1,502
Total	$	5,953	$	6,091

Note 6 - Restructuring and Other Exit Costs (Tables)

9 Months Ended

Sep. 30, 2020

Restructuring and Related Costs [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2020		2019		2020		2019
Cost of revenues	$	-	$	235	$	-	$	235
Severance costs		234		209		1,585		209
Impairment charges		-		460		-		460
Other		85		10		310		10
Restructuring and other exit costs	$	319	$	914	$	1,895	$	914

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

(in thousands)	Severance			Other			Total
Balance at December 31, 2019	$	364		$	4		$	368
Restructuring and other exit costs		1,585			310			1,895
Non-cash charges		-			(168	)		(168	)
Cash payments		(1,370	)		(117	)		(1,487	)
Balance at September 30, 2020	$	579		$	29		$	608

Note 8 - Leases (Tables)

9 Months Ended

Sep. 30, 2020

Lease, Cost [Table Text Block]

	Three Months Ended						Nine Months Ended
	September 30, 2020			September 30, 2019			September 30, 2020			September 30, 2019

Operating lease cost	$	565		$	523		$	1,647		$	1,561
Short term lease cost		46			29			131			156
Sublease income		(26	)		(104	)		(158	)		(309	)
Total lease cost	$	585		$	448		$	1,620		$	1,408

Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]

	Nine Months Ended
	September 30, 2020		September 30, 2019
	(in thousands)
Cash paid for operating lease liabilities:	$	2,041	$	1,815
Right of use assets obtained in exchange for lease obligations:	$	401	$	-

Supplemental Balance Sheet Informaton Related to Operating Leases [Table Text Block]

	September 30, 2020			December 31, 2019
	(in thousands)
Operating lease right-of use assets	$	7,927		$	8,463

Current portion, operating lease liabilities	$	2,190		$	2,424
Operating lease liabilities, long term		7,692			8,224
Total operating lease liabilities	$	9,882		$	10,648

Weighted average remaining lease term (in years)	7.6			8.1
Weighted average discount rate		9.2	%		9.2	%

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

	Operating
	Leases

2021	$	2,198
2022		1,999
2023		1,944
2024		1,897
2025		1,044
Thereafter		5,086
Total lease payments		14,168
Less interest		(4,286	)
Total operating lease liabilities	$	9,882

Note 9 - Capital Stock and Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2020

Schedule Of Stock Options And Restricted Stock Units Activity Roll forward [Table Text Block]

	Stock Options					Restricted Stock Units					Market Condition RSUs
	Stock			Weighted		Restricted					Market
	Options			Average		Stock Units			Grant Date		Condition RSUs			Grant Date
	Outstanding			Exercise Price		Outstanding			Fair Value		Outstanding			Fair Value

Balance at December 31, 2019		2,266,122		$	3.93		1,590,450		$	2.27		529,491		$	1.67
Granted		894,154			2.61		1,001,113			2.73		332,622			2.98
Exercised		(9,994	)		2.56		-			-		-			-
Vested (RSUs)		-			-		(748,096	)		2.34		(233,056	)		1.47
Cancelled/Forfeited		(253,419	)		3.43		(89,864	)		3.27		(39,286	)		3.03
Market Condition RSU - Performance Factor Adjustment		-			-		-			-		233,055			1.47
Balance at September 30, 2020		2,896,863		$	3.56		1,753,603		$	2.46		822,826		$	2.13

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(in thousands)
Cost of revenues	$	19	$	13	$	43	$	34
Sales and marketing expenses		92		39		205		68
General and administrative expenses		908		895		2,249		1,975
Research and development expenses		60		40		144		116
Total stock-based compensation expenses	$	1,079	$	987	$	2,641	$	2,193

Schedule of Weighted Average Number of Shares [Table Text Block]

	Three Months Ended				Nine Months Ended
	September 30 ,2020		September 30, 2019		September 30 ,2020		September 30, 2019
Basic		38,920,041		38,036,261		38,539,703		37,764,489
Dilutive effect of equity awards		-		-		-		-
Diluted		38,920,041		38,036,261		38,539,703		37,764,489

Monte-Carlo Valuation Simulation [Member]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Volatility	80.6	%
Risk-free interest rate	0.2	%
Correlation coefficient	0.3
Dividend Yield	-	%

Black Scholes Option Pricing Model [Member]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Volatility	58.3	%
Risk-free interest rate	0.3	%
Expected holding period (in years)	4.4
Dividend Yield	-	%

Note 10 - Long Term Debt (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of Debt [Table Text Block]

	September 30, 2020			December 31, 2019
	(in thousands)
Long-term debt:
Term loan	$	43,911		$	54,997
Revolver		450			-
Less: unamortized deferred financing costs		(885	)		(1,180	)
Total debt		43,476			53,817
Less: current installments		(3,200	)		(3,200	)
Less: excess cash flow sweep		-			(4,093	)
Current unamortized deferred financing costs		393			393
Long-term debt	$	40,669		$	46,917

Note 11 - Derivatives (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]

		September 30, 2020
		Notional Amount		Fair Value (a)
Derivatives instruments	*Balance sheet classification*	(in thousands)
Interest rate swaps	Other long term liabilities	$	24,077	$	(569	)

		December 31, 2019
		Notional Amount		Fair Value (a)
Derivatives instruments	*Balance sheet classification*	(in thousands)
Interest rate swaps	Other long term liabilities	$	28,821	$	(603	)

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Derivatives in Hedging Relationships	Amount of gain (loss) recognized in OCI on derivative (effective portion)
	Three Months Ended						Nine Months Ended
	September 30, 2020			September 30, 2019			September 30, 2020			September 30, 2019
	(in thousands)
Interest rate swaps	$	(1	)	$	(78	)	$	(228	)	$	(572	)

Details about
AOCI Components

Amount reclassified from AOCI into income (effective portion)

Three Months Ended

Nine Months Ended

Location of amount reclassified from AOCI

September 30, 2020

September 30, 2019

September 30, 2020

September 30, 2019

into income (effective portion)

(in thousands)

Interest rate swaps

262

Interest expense

Note 12 - Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Fair Value as of September 30, 2020
(in thousands)	Level 1		Level 2			Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	(569	)	$	-	$	(569	)

	Fair Value as of December 31, 2019
	Level 1		Level 2			Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	(603	)	$	-	$	(603	)

Note 13 - Revenues (Tables)

9 Months Ended

Sep. 30, 2020

Disaggregation of Revenue [Table Text Block]

	Three Months Ended September 30, 2020
(in thousands)	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	16,128	$	1,933	$	2,215	$	1,575	$	21,851
Service, maintenance and warranty contracts		1,914		229		36		7		2,186
Total revenues	$	18,042	$	2,162	$	2,251	$	1,582	$	24,037

	Three Months Ended September 30, 2019
(in thousands)	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	19,388	$	2,285	$	2,772	$	1,878	$	26,323
Service, maintenance and warranty contracts		822		198		51		24		1,095
Total revenues	$	20,210	$	2,483	$	2,823	$	1,902	$	27,418

	Nine Months Ended September 30, 2020
(in thousands)	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	48,574	$	6,432	$	7,170	$	4,681	$	66,857
Service, maintenance and warranty contracts		3,459		644		109		47		4,259
Total revenues	$	52,033	$	7,076	$	7,279	$	4,728	$	71,116

	Nine Months Ended September 30, 2019
(in thousands)	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	58,979	$	7,814	$	8,956	$	5,675	$	81,424
Service, maintenance and warranty contracts		2,874		624		227		55		3,780
Total revenues	$	61,853	$	8,438	$	9,183	$	5,730	$	85,204

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

	Three Months Ended September 30, 2020
(in thousands)	Service Contracts			Customer Advances			Total
Balance at June 30, 2020	$	1,413		$	2,239		$	3,652
Deferral of revenue		1,126			198			1,324
Recognition of deferred revenue		(1,041	)		(387	)		(1,428	)
Effect of foreign currency translation		11			-			11
Balance at September 30, 2020	$	1,509		$	2,050		$	3,559

	Three Months Ended September 30, 2019
(in thousands)	Service Contracts			Customer Advances			Total
Balance at June 30, 2019	$	1,593		$	1,939		$	3,532
Deferral of revenue		471			310			781
Recognition of deferred revenue		(358	)		(421	)		(779	)
Effect of foreign currency translation		16			-			16
Balance at September 30, 2019	$	1,722		$	1,828		$	3,550

	Nine Months Ended September 30, 2020
(in thousands)	Service Contracts			Customer Advances			Total
Balance at December 31, 2019	$	1,587		$	2,362		$	3,949
Deferral of revenue		1,956			542			2,498
Recognition of deferred revenue		(2,029	)		(854	)		(2,883	)
Effect of foreign currency translation		(5	)		-			(5	)
Balance at September 30, 2020	$	1,509		$	2,050		$	3,559

	Nine Months Ended September 30, 2019
(in thousands)	Service Contracts			Customer Advances			Total
Balance at December 31, 2018	$	1,659		$	2,161		$	3,820
Deferral of revenue		1,597			561			2,158
Recognition of deferred revenue		(1,550	)		(894	)		(2,444	)
Effect of foreign currency translation		16			-			16
Balance at September 30, 2019	$	1,722		$	1,828		$	3,550

Financing Receivable, Allowance for Credit Loss [Table Text Block]

	Nine Months Ended September 30,
	2020			2019

Balance, beginning of period	$	325		$	332
Bad debt expense		24			394
Charge-offs and other recoveries		(60	)		(354	)
Effect of foreign currency translation		4			(8	)
Balance, end of period	$	293		$	364

Note 3 - Accumulated Other Comprehensive Loss - Changes in Each Component of Other Comprehensive Loss, Net of Tax (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Balance	$ 76,068	$ 80,330	$ 81,694	$ 82,724
Other comprehensive (loss) income	1,730	(1,536)	715	(2,185)
Balance	77,167	77,103	77,167	77,103
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance			(13,173)
Other comprehensive income (loss) before reclassifications			681
Amounts reclassified from AOCI into income			0
Other comprehensive (loss) income			681
Balance	(12,492)		(12,492)
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]
Balance			(603)
Other comprehensive income (loss) before reclassifications			(228)
Amounts reclassified from AOCI into income			262
Other comprehensive (loss) income			34
Balance	(569)		(569)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Balance			1,087
Other comprehensive income (loss) before reclassifications			0
Amounts reclassified from AOCI into income			0
Other comprehensive (loss) income			0
Balance	1,087		1,087
AOCI Attributable to Parent [Member]
Balance	(13,704)	(14,181)	(12,689)	(13,532)
Other comprehensive income (loss) before reclassifications			453
Amounts reclassified from AOCI into income			262
Other comprehensive (loss) income	1,730	(1,536)	715	(2,185)
Balance	$ (11,974)	$ (15,717)	$ (11,974)	$ (15,717)

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

Note 4 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Jan. 01, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Reclassification of Intangible Assets		$ 68,358		$ 68,358		$ 67,023
Amortization of Intangible Assets, Total		$ 1,377	$ 1,422	$ 4,258	$ 4,289
Indefinite-Lived Trade Names Reclassified to Finite-Lived [Member]
Reclassification of Intangible Assets	$ 900
Finite-Lived Intangible Asset, Useful Life (Year)	4 years

Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020 USD ($)
Carrying amount at December 31, 2019	$ 57,381
Effect of change in currency translation	266
Carrying amount at September 30, 2020	$ 57,647

Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)
$ in Thousands

9 Months Ended

Sep. 30, 2020

Dec. 31, 2019

$ 68,358

$ 67,023

(34,287)

(29,753)

Indefinite-lived intangible assets:

34,071

37,270

244

1,135

Total intangible assets, Net

$ 34,315

38,405

Distribution Agreements/Customer Relationships [Member]

Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)

^[1]

9 years 1 month 6 days

$ 18,130

17,891

(7,400)

(6,340)

Existing Technology [Member]

$ 10,730

11,551

Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)

^[1]

5 years 4 months 24 days

$ 41,347

41,222

(22,524)

(19,698)

Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)

$ 18,823

21,524

Trade Names [Member]

^[1]

5 years 8 months 12 days

$ 8,668

7,692

(4,150)

(3,497)

4,518

4,195

Patents [Member]

213

218

(213)

(218)

Other Noncurrent Liabilities [Member]

$ 0

[1]	Weighted average life as of September 30, 2020.

Note 4 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
2020 (remainder of year)	$ 1,676
2021	5,703
2022	5,672
2023	5,569
2024	5,267
Thereafter	10,184
Total	$ 34,071	$ 37,270

Note 5 - Balance Sheet Information - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Finished goods	$ 5,311	$ 5,561
Work in process	3,897	3,153
Raw materials	13,481	13,347
Total	$ 22,689	$ 22,061

Note 5 - Balance Sheet Information - Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Compensation and payroll	$ 2,218	$ 2,554
Professional fees	594	395
Warranty costs	184	252
Customer related costs	1,038	963
Interest	376	425
Other	1,543	1,502
Total	$ 5,953	$ 6,091

Note 6 - Restructuring and Other Exit Costs (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Asset Impairment Charges, Total	$ 0	$ 460	$ 0	$ 1,401
Restructuring Charges, Total	319	914	1,895	914
Restructuring Reserve, Ending Balance	608		608		$ 368
Facility Closing [Member]
Restructuring Charges, Total	$ 0	$ 460	$ 0	460
In Process Research and Development [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total				$ 900

Note 6 - Restructuring and Other Exit Costs - Restructuring and Other Exit Charges (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Restructuring and other exit costs	$ 319	$ 914	$ 1,895	$ 914
Cost of Revenues [Member]
Restructuring and other exit costs	0	235	0	235
Employee Severance [Member]
Restructuring and other exit costs	234	209	1,585	209
Facility Closing [Member]
Restructuring and other exit costs	0	460	0	460
Other Restructuring [Member]
Restructuring and other exit costs	$ 85	$ 10	$ 310	$ 10

Note 6 - Restructuring and Other Exit Costs - Activity for Accrued Restructuring Liability (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Balance			$ 368
Restructuring and other exit costs	$ 319	$ 914	1,895	$ 914
Non-cash charges			(168)
Cash payments			(1,487)
Balance	608		608
Employee Severance [Member]
Balance			364
Restructuring and other exit costs	234	209	1,585	209
Non-cash charges			0
Cash payments			(1,370)
Balance	579		579
Other Restructuring [Member]
Balance			4
Restructuring and other exit costs	85	$ 10	310	$ 10
Non-cash charges			(168)
Cash payments			(117)
Balance	$ 29		$ 29

Note 7 - Related Party Transactions (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Multi Channel Systems MCS GmbH [Member]
Operating Leases, Rent Expense, Net, Total	$ 0.1	$ 0.1	$ 0.2	$ 0.3

Note 8 - Leases - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating lease cost	$ 565	$ 523	$ 1,647	$ 1,561
Short term lease cost	46	29	131	156
Sublease income	(26)	(104)	(158)	(309)
Total lease cost	$ 585	$ 448	$ 1,620	$ 1,408

Note 8 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash paid for operating lease liabilities:	$ 2,041	$ 1,815
Right of use assets obtained in exchange for lease obligations:	$ 401	$ 0

Note 8 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Operating lease right-of use assets	$ 7,927	$ 8,463
Current portion, operating lease liabilities	2,190	2,424
Operating lease liabilities, long term	7,692	8,224
Total operating lease liabilities	$ 9,882	$ 10,648
Weighted average remaining lease term (in years) (Year)	7 years 7 months 6 days	8 years 1 month 6 days
Weighted average discount rate	9.20%	9.20%

Note 8 - Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
2021	$ 2,198
2022	1,999
2023	1,944
2024	1,897
2025	1,044
Thereafter	5,086
Total lease payments	14,168
Less interest	(4,286)
Total operating lease liabilities	$ 9,882	$ 10,648

Note 9 - Capital Stock and Stock-based Compensation (Details Textual) $ / shares in Units, $ in Millions			9 Months Ended
	Jun. 11, 2020 shares	May 16, 2019	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2019 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	3,700,000
Fungible Share Ratio for Deferred Stock Awards	1.49	1.79
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)			3,288,084
Restricted Stock Units Ratio			1.49
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total \| $			$ 5.4
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			2 years 4 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) \| $ / shares			$ 1.21	$ 1.21
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)			5,473,292	4,055,076
Market Condition Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) \| $ / shares			$ 2.98

Note 9 - Capital Stock and Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)	9 Months Ended
	Sep. 30, 2020 $ / shares shares
Options, outstanding (in shares) \| shares	2,266,122
Options, outstanding, weighted average exercise price (in dollars per share) \| $ / shares	$ 3.93
Options, granted (in shares) \| shares	894,154
Options, granted, weighted average exercise price (in dollars per share) \| $ / shares	$ 2.61
Options, exercised (in shares) \| shares	(9,994)
Options, exercised, weighted average exercise price (in dollars per share) \| $ / shares	$ 2.56
Options, cancelled / forfeited (in shares) \| shares	(253,419)
Options, cancelled / forfeited, weighted average exercise price (in dollars per share) \| $ / shares	$ 3.43
Options, outstanding (in shares) \| shares	2,896,863
Options, outstanding, weighted average exercise price (in dollars per share) \| $ / shares	$ 3.56
Restricted Stock Units (RSUs) [Member]
Restricted stock units, outstanding (in shares) \| shares	1,590,450
Restricted stock units, outstanding, grant date fair value (in dollars per share) \| $ / shares	$ 2.27
Restricted stock units, granted (in shares) \| shares	1,001,113
Restricted stock units, granted, grant date fair value (in dollars per share) \| $ / shares	$ 2.73
Restricted stock units, vested (in shares) \| shares	(748,096)
Restricted stock units, vested, grant date fair value (in dollars per share) \| $ / shares	$ 2.34
Restricted stock units, cancelled / forfeited (in shares) \| shares	(89,864)
Restricted stock units, cancelled / forfeited, grant date fair value (in dollars per share) \| $ / shares	$ 3.27
Market Condition RSU - Performance Factor Adjustment (in shares) \| shares	0
Market Condition RSU - Performance Factor Adjustment (in dollars per share) \| $ / shares	$ 0
Restricted stock units, outstanding (in shares) \| shares	1,753,603
Restricted stock units, outstanding, grant date fair value (in dollars per share) \| $ / shares	$ 2.46
Market Condition Restricted Stock Units [Member]
Restricted stock units, outstanding (in shares) \| shares	529,491
Restricted stock units, outstanding, grant date fair value (in dollars per share) \| $ / shares	$ 1.67
Restricted stock units, granted (in shares) \| shares	332,622
Restricted stock units, granted, grant date fair value (in dollars per share) \| $ / shares	$ 2.98
Restricted stock units, vested (in shares) \| shares	(233,056)
Restricted stock units, vested, grant date fair value (in dollars per share) \| $ / shares	$ 1.47
Restricted stock units, cancelled / forfeited (in shares) \| shares	(39,286)
Restricted stock units, cancelled / forfeited, grant date fair value (in dollars per share) \| $ / shares	$ 3.03
Market Condition RSU - Performance Factor Adjustment (in shares) \| shares	233,055
Market Condition RSU - Performance Factor Adjustment (in dollars per share) \| $ / shares	$ 1.47
Restricted stock units, outstanding (in shares) \| shares	822,826
Restricted stock units, outstanding, grant date fair value (in dollars per share) \| $ / shares	$ 2.13

Note 9 - Capital Stock and Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based compensation	$ 1,079	$ 987	$ 2,641	$ 2,193
Continuing Operations [Member] \| Cost of Sales [Member]
Share-based compensation	19	13	43	34
Continuing Operations [Member] \| Selling and Marketing Expense [Member]
Share-based compensation	92	39	205	68
Continuing Operations [Member] \| General and Administrative Expense [Member]
Share-based compensation	908	895	2,249	1,975
Continuing Operations [Member] \| Research and Development Expense [Member]
Share-based compensation	$ 60	$ 40	$ 144	$ 116

Note 9 - Capital Stock and Stock-based Compensation - Black Scholes Assumptions (Details) - Black Scholes Option Pricing Model [Member]	9 Months Ended
	Sep. 30, 2020
Volatility	58.30%
Risk-free interest rate	0.30%
Expected holding period (Year)	4 years 4 months 24 days
Dividend Yield	0.00%

Note 9 - Capital Stock and Stock-based Compensation - Monte Carlo Assumptions (Details) - Monte-Carlo Valuation Simulation [Member]	9 Months Ended
	Sep. 30, 2020
Volatility	80.60%
Risk-free interest rate	0.20%
Correlation coefficient	0.30%
Dividend Yield	0.00%

Note 9 - Capital Stock and Stock-based Compensation - Weighted Average Number of Shares (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Basic (in shares)	38,920,041	38,036,261	38,539,703	37,764,489
Dilutive effect of equity awards (in shares)	0	0	0	0
Diluted (in shares)	38,920,041	38,036,261	38,539,703	37,764,489

Note 10 - Long Term Debt (Details Textual) $ in Thousands			9 Months Ended
Note 10 - Long Term Debt (Details Textual) $ in Thousands	May 04, 2020 USD ($)	Apr. 18, 2020 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Dec. 31, 2019 USD ($)	Jan. 31, 2018 USD ($)
Repayments of Long-term Debt, Total			$ 20,251	$ 11,103
Term Loan [Member]
Line of Credit Facility, Interest Rate at Period End			8.90%
Senior Secured Credit Facility [Member] \| Maximum [Member]
Debt Instrument, Leverage Ratio			3.25
Senior Secured Credit Facility [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity						$ 25,000
Line of Credit Facility, Remaining Borrowing Capacity			$ 7,300
Paycheck Protection Program CARES Act [Member]
Repayments of Long-term Debt, Total	$ 6,100
Proceeds from Issuance of Long-term Debt, Total		$ 6,100
Term Loan [Member]
Long-term Debt, Gross			43,911		$ 54,997
Term Loan [Member] \| Senior Secured Credit Facility [Member]
Long-term Debt, Gross						$ 64,000
Repayments of Long-term Debt, Total			$ 4,700

Note 10 - Long Term Debt - Breakdown of Borrowings (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Less: unamortized deferred financing costs	$ (885)	$ (1,180)
Total debt	43,476	53,817
Less: current installments	(3,200)	(3,200)
Less: excess cash flow sweep	0	(4,093)
Current unamortized deferred financing costs	393	393
Long-term debt	40,669	46,917
Term Loan [Member]
Long-term debt, gross	43,911	54,997
Line of Credit [Member]
Long-term debt, gross	$ 450	$ 0

Note 11 - Derivatives (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Jan. 31, 2018
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	$ (300)
Interest Rate Swap [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Derivative, Fixed Interest Rate			2.72%
Interest Rate Swap [Member] \| PNC Bank [Member]
Derivative Asset, Notional Amount			$ 36,000
Term Loan [Member]
Long-term Debt, Gross	$ 43,911	$ 54,997
Senior Secured Credit Facility [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			25,000
Senior Secured Credit Facility [Member] \| Term Loan [Member]
Long-term Debt, Gross			$ 64,000

Note 11 - Derivatives - Derivative Instruments (Details) - Interest Rate Swap [Member] - Cash Flow Hedging [Member] - USD ($)
$ in Thousands

Sep. 30, 2020

Dec. 31, 2019

Derivatives, notional amount

$ 24,077

Derivatives, fair value

^[1]

$ (569)

Other Assets [Member]

Derivatives, notional amount

$ 28,821

Derivatives, fair value

^[1]

$ (603)

[1]	See Note 12 for the fair value measurements related to these financial instruments.

Note 11 - Derivatives - Effect of Derivatives on AOCI (Details) - Interest Rate Swap [Member] - Cash Flow Hedging [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Amount of loss recognized in OCI on derivative	$ (1)	$ (78)	$ (228)	$ (572)
Interest Expense [Member]
Amount reclassified from AOCI into income	$ 93	$ 37	$ 262	$ 73

Note 12 - Fair Value of Financial Instruments - Assets and Liabilities Measured on a Recurring Basis (Details) - Interest Rate Swap [Member] - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Derivative liabilities	$ (569)	$ (603)
Fair Value, Inputs, Level 1 [Member]
Derivative liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Derivative liabilities	(569)	(603)
Fair Value, Inputs, Level 3 [Member]
Derivative liabilities	$ 0	$ 0

Note 13 - Revenues (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2018
Contract with Customer, Liability, Total	$ 3,559	$ 3,652	$ 3,949	$ 3,550	$ 3,532	$ 3,820

Note 13 - Revenues - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues	$ 24,037	$ 27,418	$ 71,116	$ 85,204
Instruments, Equipment, Software, and Accessories [Member]
Revenues	21,851	26,323	66,857	81,424
Service, Maintenance, and Warranty Contracts [Member]
Revenues	2,186	1,095	4,259	3,780
UNITED STATES
Revenues	18,042	20,210	52,033	61,853
UNITED STATES \| Instruments, Equipment, Software, and Accessories [Member]
Revenues	16,128	19,388	48,574	58,979
UNITED STATES \| Service, Maintenance, and Warranty Contracts [Member]
Revenues	1,914	822	3,459	2,874
UNITED KINGDOM
Revenues	2,162	2,483	7,076	8,438
UNITED KINGDOM \| Instruments, Equipment, Software, and Accessories [Member]
Revenues	1,933	2,285	6,432	7,814
UNITED KINGDOM \| Service, Maintenance, and Warranty Contracts [Member]
Revenues	229	198	644	624
GERMANY
Revenues	2,251	2,823	7,279	9,183
GERMANY \| Instruments, Equipment, Software, and Accessories [Member]
Revenues	2,215	2,772	7,170	8,956
GERMANY \| Service, Maintenance, and Warranty Contracts [Member]
Revenues	36	51	109	227
Rest of the World [Member]
Revenues	1,582	1,902	4,728	5,730
Rest of the World [Member] \| Instruments, Equipment, Software, and Accessories [Member]
Revenues	1,575	1,878	4,681	5,675
Rest of the World [Member] \| Service, Maintenance, and Warranty Contracts [Member]
Revenues	$ 7	$ 24	$ 47	$ 55

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Note 13 - Revenues - Changes in Deferred Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Balance	$ 3,652	$ 3,532	$ 3,949	$ 3,820
Deferral of revenue	1,324	781	2,498	2,158
Recognition of deferred revenue	(1,428)	(779)	(2,883)	(2,444)
Effect of foreign currency translation	11	16	(5)	16
Balance	3,559	3,550	3,559	3,550
Service [Member]
Balance	1,413	1,593	1,587	1,659
Deferral of revenue	1,126	471	1,956	1,597
Recognition of deferred revenue	(1,041)	(358)	(2,029)	(1,550)
Effect of foreign currency translation	11	16	(5)	16
Balance	1,509	1,722	1,509	1,722
Customer Advances [Member]
Balance	2,239	1,939	2,362	2,161
Deferral of revenue	198	310	542	561
Recognition of deferred revenue	(387)	(421)	(854)	(894)
Effect of foreign currency translation	0	0	0	0
Balance	$ 2,050	$ 1,828	$ 2,050	$ 1,828

Note 13 - Revenues - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Balance, beginning of period	$ 325	$ 332
Bad debt expense	24	394
Charge-offs and other recoveries	(60)	(354)
Effect of foreign currency translation	4	(8)
Balance, end of period	$ 293	$ 364

Note 14 - Income Tax (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Expense (Benefit), Total	$ (317)	$ (54)	$ 451	$ (363)
Effective Income Tax Rate Reconciliation, Percent, Total	22.40%	2.00%	(6.70%)	6.50%

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.